The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar i disorder: An 8-week, multicenter, open-label study

Clinical Drug Investigation

Volumn 33, Issue 10, 2013, Pages 743-753

  Lee, Hwang Bin ^a   Yoon, Bo Hyun ^b   Kwon, Young Joon ^c   Woo, Young Sup ^d   Lee, Jung Goo ^e   Kim, Moon Doo ^f   Bahk, Won Myong ^d  

^a Seoul National University Hospital   (South Korea)

^b Department of Psychiatry   (South Korea)

^c Soonchunhyang University   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Jeju National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LITHIUM; OLANZAPINE; TRIACYLGLYCEROL; VALPROIC ACID; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR I DISORDER; BODY MASS; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSLIPIDEMIA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HOSPITAL PATIENT; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RESTLESSNESS; RIGIDITY; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; TREMOR; VITAL SIGN; VOMITING; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; LITHIUM; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; THIAZOLES; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 84885097109     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0120-y     Document Type: Article

References (47)

1. Stokes PE, Shamoian CA, Stoll PM, et al. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet. 1971;1(7713):1319-25.
2. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 1991;48(1):62-8.
3. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994;271(12):918-24.
4. Post RM, Ketter TA, Pazzaglia PJ, et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res Suppl. 1996;11:153-80.
5. Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry. 2005;66(Suppl 3):12-9.
6. Zarate CA Jr, Quiroz JA. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord. 2003;5(3):217-25.
7. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7):870-86.
8. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225-55.
9. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85-116.
10. Jon DI, Bahk WM, Yoon BH, et al. Revised Korean medication algorithm for bipolar disorder. World J Biol Psychiatry. 2009;10(4 Pt 3):846-55.
11. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59(1):62-9.
12. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004;184:337-45.
13. Treuer T, Hoffmann VP, Chen AK, et al. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry. 2009;10(4 Pt 3):729-40.
14. Citrome L, Holt RI, Walker DJ, et al. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31(7):455-82.
15. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-50.
16. Laursen TM, Munk-Olsen T, Nordentoft M, et al. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007;68(6):899-907.
17. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23(1):40-7.
18. Cardenas J, Frye MA, Marusak SL, et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008;106(1-2):91-7.
19. McIntyre RS, Danilewitz M, Liauw SS, et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord. 2010;126(3):366-87.
20. Hennen J, Perlis RH, Sachs G, et al. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry. 2004;65(12):1679-87.
21. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res. 2004;12(2):362-8.
22. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160(4):741-8.
23. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25(4):301-10.
24. Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry. 2010;71(2):130-7.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association; 2000.
26. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-35.
27. Vieta E, T'Joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008;165(10):1316-25.
28. Houston JP, Ketter TA, Case M, et al. Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes. J Psychiatr Res. 2011;45(2):169-73.
29. Kemp DE, Johnson E, Wang WV, et al. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. J Clin Psychiatry. 2011;72(9):1236-41.
30. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
31. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:790-812.
32. Guy W. Clinical global impressions: In: ECDEU assessment manual for psychopharmacology. Rockville: National Institute for Mental Health; 1976. p. 217-22
33. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(Suppl 3):133-8.
34. Kim S-W, Shin I-S, Kim J-M, et al. A validation study of the Korean version of the Subjective Well-being Under Neuroleptic Treatment Scale-Short Form. Korean J Psychopharmacol. 2007;18(4):221-30.
35. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-83.
36. Yoon B, Bahk W, Lee K, et al. Psychometric properties of Korean version of Drug Attitude Inventory (KDAI-10). Korean J Psychopharmacol. 2005;16:480-7.
37. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-9.
38. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-6.
39. Vieta E, Ramey T, Keller D, et al. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol. 2010;24(4):547-58.
40. Alptekin K, Hafez J, Brook S, et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol. 2009;24(5):229-38.
41. Simpson GM, O'Gorman CJ, Loebel A, et al. Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia. CNS Spectr. 2008;13(10):898-905.
42. Keck PE Jr, Versiani M, Warrington L, et al. Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. J Clin Psychiatry. 2009;70(6):844-51.
43. Kemp DE, Karayal ON, Calabrese JR, et al. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. Eur Neuropsychopharmacol. 2011;22:123-31.
44. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20(5):491-505.
45. Kinon BJ, Kaiser CJ, Ahmed S, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25(3):255-8.
46. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-33.
47. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008;33(5):985-94.